Participant Recruitment and Eligibility
T2D
Individuals with T2D from the North East of England were recruited by study advertisements. Inclusion criteria were age 30 to 60 years, duration of T2D of ≥ 1 year, stable treatment with lifestyle and/or oral medications for ≥ 3 months, glycated hemoglobin (HbAParticipant recruitment and testing were conducted between March 2019 and September 2021. A total of 26 participants were recruited for this study. From this cohort, 8 participants were withdrawn for the following reasons: 1 participant withdrew their consent prior to randomization; 3 participants were withdrawn due abnormal laboratory findings (laboratory measured HbAParticipant flow through a randomized, placebo-controlled crossover trial.Patient clinical characteristicsWhere appropriate, data are presented as means ± SD (range).Abbreviations: SGLT2i, sodium-glucose cotransporter 2 inhibitor; SU, sulfonylureas; TZD, thiazolidinediones.